ArrowMark Colorado Holdings LLC Sells 500,144 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

ArrowMark Colorado Holdings LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 24.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,510,511 shares of the biopharmaceutical company's stock after selling 500,144 shares during the period. ArrowMark Colorado Holdings LLC owned about 1.19% of Halozyme Therapeutics worth $72,218,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. AXA S.A. raised its stake in shares of Halozyme Therapeutics by 22.1% during the 4th quarter. AXA S.A. now owns 131,891 shares of the biopharmaceutical company's stock worth $6,306,000 after purchasing an additional 23,835 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec increased its holdings in Halozyme Therapeutics by 280.4% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 357,579 shares of the biopharmaceutical company's stock worth $17,096,000 after buying an additional 263,570 shares during the last quarter. Freestone Grove Partners LP bought a new stake in Halozyme Therapeutics during the fourth quarter worth $327,000. PDT Partners LLC lifted its stake in Halozyme Therapeutics by 382.7% in the fourth quarter. PDT Partners LLC now owns 84,062 shares of the biopharmaceutical company's stock valued at $4,019,000 after acquiring an additional 66,647 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock valued at $87,386,000 after acquiring an additional 145,617 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock traded down $0.57 during trading on Monday, reaching $60.62. The company's stock had a trading volume of 905,972 shares, compared to its average volume of 1,441,596. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The business's 50-day moving average price is $60.85 and its 200-day moving average price is $55.46. Halozyme Therapeutics, Inc. has a 52 week low of $40.19 and a 52 week high of $66.00. The firm has a market cap of $7.49 billion, a PE ratio of 17.67, a P/E/G ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the transaction, the director now owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,697 shares of company stock valued at $1,276,552 over the last 90 days. 2.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Friday, April 25th. Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Benchmark reissued a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.